Suraksha Diagnostic Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 4.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suraksha Diagnostic reported strong revenue growth for FY2026 with standalone revenue up 20.7% to ₹30,068 lakhs from ₹24,910 lakhs in FY2025. Consolidated revenue grew 23.2% to ₹31,041 lakhs. Standalone profit after tax increased marginally by 1.9% to ₹3,406 lakhs, while consolidated PAT rose 1.4% to ₹3,140 lakhs. The company declared a dividend of ₹0.50 per equity share (25%) for FY2025-26, compared to nil dividend in the previous year. Auditors MSKA & Associates issued an unmodified (clean) opinion on both standalone and consolidated results. A step-down subsidiary is involved in a dispute with the Government of Meghalaya, with ₹392.20 lakhs in investments and loans under assessment. The company also completed acquisition of Fetomat Wellness Private Limited in April 2025.
Revenue growth of over 20% is positive, but profit growth lagging at under 2% suggests margin pressure. The dividend resumption signals management confidence. The dispute in the step-down subsidiary involving government entities adds some risk visibility.